Rebecca Pagnard
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1376991547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,901, 6.0 times the $317 reported in 2021.
Across 250 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$597
- Lilly USA, LLC$533
- Abbott$521
- Dexcom, Inc.$433
- Corcept Therapeutics$385
- Amneal Pharmaceuticals LLC$273
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,425100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $597 |
| Lilly USA, LLC | 29 | $533 |
| Abbott | 23 | $521 |
| Dexcom, Inc. | 20 | $433 |
| Corcept Therapeutics | 16 | $385 |
| Amneal Pharmaceuticals LLC | 25 | $273 |
| AbbVie | 14 | $266 |
| Medtronic | 6 | $227 |
| Amgen(2 entities) | 14 | $222 |
| Boehringer Ingelheim | 4 | $172 |
| Madrigal Pharmaceuticals | 2 | $165 |
| Insulet Corporation | 6 | $155 |
| Sequel Med Tech, LLC | 1 | $147 |
| Mannkind Corporation | 7 | $139 |
| Xeris Pharmaceuticals, Inc. | 7 | $134 |
| Neurocrine Biosciences, Inc. | 4 | $109 |
| Ascendis Pharma Endocrinology Inc | 4 | $100 |
| Antares Pharma, Inc. | 6 | $84 |
| Halozyme Inc | 4 | $74 |
| Novartis | 3 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Recordati_rare_diseases_inc. | 3 | $66 |
| Tandem Diabetes Care, Inc. | 1 | $65 |
| AstraZeneca(2 entities) | 3 | $56 |
| Tolmar, Inc. | 3 | $54 |
| Cequr Corporation | 1 | $44 |
| Verity Pharmaceuticals Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $34 |
| Sandoz | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Embecta Corp. | 1 | $14 |
| Intuity Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$149
- TWIIST$147
- MINIMED 780G$140
- JARDIANCE$110
- FREESTYLE LIBRE 3$103
- Ozempic$102
How this compares
$5,425 in reported general payments places this provider in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 194 | $349,205 |
| MounjaroTirzepatide | 179 | $281,171 |
| TrulicityDulaglutide | 103 | $167,573 |
| JardianceEmpagliflozin | 114 | $164,657 |
| FarxigaDapagliflozin Propanediol | 86 | $117,552 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $91,858 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $82,997 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $76,140 |
| RybelsusSemaglutide | 17 | $45,265 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $30,449 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $23,598 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $20,769 |
| VascepaIcosapent Ethyl | 28 | $17,424 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $13,924 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $10,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $533 | $459,106315 claims |
| Novo NordiskOzempic, Rybelsus | $597 | $394,470211 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $172 | $188,255130 claims |
| AstraZenecaFarxiga | $56 | $117,55286 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $68 | $20,76912 claims |
| AbbVieSynthroid | $266 | $8,27280 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $273 | $5,305505 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.